Figure 3

Role of the leech TRPV-like receptor and GABA during 2AG-mediated synaptic potentiation. (A) The TRPV1 antagonist, SB366791 (10 μM), prevents potentiation of the non-nociceptive P-to-L synapses that is normally observed following 2AG treatment. Asterisks indicate statistically significant difference relative to the vehicle control group (see Results section for details). (B) Role of GABA signaling during 2AG-mediated synaptic potentiation. Pretreatment of synapses with the GABA receptor antagonist bicuculline (100 μM), prevented 2AG-induced potentiation of the non-nociceptive N-to-L synapse. Asterisks indicate statistically significant difference relative to the vehicle control group (see Results section for details).